Story
Blackstone Private Equity Head Joe Baratta Reportedly in Exit Talks
Summary
Joe Baratta, a 28-year veteran and head of private equity strategies at Blackstone, is reportedly in discussions to leave the firm by year-end, marking another high-profile leadership change at the asset manager.
Joe Baratta, the head of Blackstone Inc.'s (NYSE: BX) private equity strategies and a key figure at the firm for nearly three decades, is in talks to depart by the end of the year, according to a Bloomberg report citing people familiar with the matter.
A Veteran Dealmaker's Departure
Baratta has been a prominent face of Blackstone's flagship buyout business since joining the firm in 1998. He led the private equity division for approximately 13 years before transitioning in 2025 to a new role overseeing the firm's private equity strategies worldwide.
His potential departure would conclude a 28-year career during which he was instrumental in some of the firm's most significant deals. As one of Blackstone's most senior investment professionals, his exit would represent a major change for its largest and most well-known business unit.
AdContext of Leadership Changes
The move follows other senior leadership changes at the alternative asset management giant this year. Blackstone has also seen the departures of real estate head Nadeem Meghji and growth strategy head Jon Korngold in 2026.
A transition in a core division like private equity can have significant implications for asset managers. Such high-level departures often raise questions among investors and limited partners about succession planning and the future direction of the firm's strategy.
Read next
More on Stocks
Erste Group Bids for Majority Stake in Erste Bank Polska With Tender Offer
The Austrian lender plans to launch a cash tender offer for up to 26% of its Polish subsidiary at a discount to the market price, aiming to secure a controlling interest.
Mirum Pharmaceuticals Wins FDA Approval for Rare Bone Disorder Drug Atebrioz
The U.S. Food and Drug Administration has approved Mirum Pharmaceuticals' drug, Atebrioz (zilurgisertib), for treating fibrodysplasia ossificans progressiva (FOP), a rare genetic condition causing abnormal bone growth.
Rithm Capital Credit Rating Raised to 'B+' by S&P on Successful Diversification
S&P Global Ratings upgraded Rithm Capital's credit rating to 'B+' with a stable outlook, crediting the firm's significant expansion into asset management and private credit, which has reduced its reliance on traditional mortgage finance.
US Appeals Court Rules States Can Regulate Kalshi's Prediction Markets
A federal appeals court has ruled that states can regulate Kalshi's event contracts under local gambling laws, a decision that rejects the prediction market's bid for exclusive federal oversight by the CFTC.